CD47 and glioblastoma: Additional studies are necessary to address the relationship between efficacy of anti-CD47 treatment and the density of TAMs in human GBMs, and the feasibility of combining CD47 blocking immunotherapy with cytokines that modulate macrophage recruitment and activation to treat GBM in patients.